$2.32
0.00%
Nasdaq, Apr 21, 09:09 pm CET
ISIN
US05479K1060
Symbol
ELUT
Sector
Industry

Aziyo Biologics Inc - Ordinary Shares - Class A Stock price

$2.32
-0.88 27.50% 1M
-1.27 35.29% 6M
-1.42 37.97% YTD
-0.72 23.68% 1Y
-5.09 68.69% 3Y
-14.68 86.35% 5Y
-14.68 86.35% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.22 10.48%
ISIN
US05479K1060
Symbol
ELUT
Sector
Industry

Key metrics

Market capitalization $94.81m
Enterprise Value $116.20m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.77
P/S ratio (TTM) P/S ratio 3.89
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -31.04%
Revenue (TTM) Revenue $24.38m
EBIT (operating result TTM) EBIT $-24.28m
Free Cash Flow (TTM) Free Cash Flow $-23.31m
Cash position $13.24m
EPS (TTM) EPS $-2.48
P/E forward negative
P/S forward 2.85
EV/Sales forward 3.49
Short interest 0.25%
Show more

Is Aziyo Biologics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Aziyo Biologics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:

Buy
100%

Financial data from Aziyo Biologics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
24 24
31% 31%
100%
- Direct Costs 14 14
41% 41%
56%
11 11
13% 13%
44%
- Selling and Administrative Expenses 28 28
11% 11%
114%
- Research and Development Expense 3.79 3.79
23% 23%
16%
-21 -21
18% 18%
-85%
- Depreciation and Amortization 3.45 3.45
7% 7%
14%
EBIT (Operating Income) EBIT -24 -24
14% 14%
-100%
Net Profit -54 -54
24% 24%
-222%

In millions USD.

Don't miss a Thing! We will send you all news about Aziyo Biologics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aziyo Biologics Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
about 8 hours ago
— Integration of clinical and patient-reported outcomes expected to further differentiate EluPro's utility in cardiac implantable electronic device (CIED) procedures — SILVER SPRING, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the initiation of an EluPro™ clinical study designed...
Neutral
GlobeNewsWire
7 days ago
SILVER SPRING, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today confirmed that the ongoing global tariff environment has had no material impact on its commercial or operational performance.
Neutral
GlobeNewsWire
18 days ago
SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences:
More Aziyo Biologics Inc - Ordinary Shares - Class A News

Company Profile

Aziyo Biologics, Inc. operates as a biotechnology company which focuses on regenerative medicine in areas such as cardiology, orthopedics and other medical specialties. It offers cardiac device envelope, vascular surgery, cardiothoracic repair, orthopedics and spine, sports medicine, dermal, and wound care. The company was founded on August 6, 2015 and is headquartered in Silver Spring, MD.

Head office United States
CEO Charles Mills
Employees 51
Founded 2015
Website www.elutia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today